Kiniksa Pharmaceuticals International (KNSA) Revenue (2021 - 2026)
Kiniksa Pharmaceuticals International's (KNSA) quarterly Revenue came in at $243.6 million in Q2 2026, up 55.36% on a YoY basis from $156.8 million in Q2 2025, and up 13.69% quarter-over-quarter from $214.3 million in Q1 2026.
Powered by 
Analysis
Kiniksa Pharmaceuticals International (KNSA) Revenue (2021 - 2026) Analysis & Trends
Kiniksa Pharmaceuticals International (KNSA) has reported Revenue for 6 consecutive years, with $243.6 million the latest figure, recorded in Q2 2026.
- For the quarter ending Q2 2026, Revenue rose 55.36% year-over-year to $243.6 million; the trailing twelve-month figure through Jun 2026 stood at $840.8 million (up 58.85% YoY), and the FY2025 full-year result was $677.6 million, up 60.09% from the prior year.
- Revenue improved to $243.6 million in Q2 2026 per KNSA's latest filing, from $214.3 million in the prior quarter.
- Across five years, Revenue topped out at $243.6 million in Q2 2026 and bottomed at $27.0 million in Q2 2022.
- Historically, Revenue has averaged $113.8 million across 5 years, with a median of $103.9 million in 2022.
- The sharpest annual moves came in 2022 and 2023: Revenue jumped 719.64% in 2022, then slumped 32.37% in 2023.
- Over 5 years, Revenue stood at $61.9 million in 2022, then soared by 34.76% to $83.4 million in 2023, then soared by 46.93% to $122.5 million in 2024, then jumped by 64.95% to $202.1 million in 2025, then increased by 20.52% to $243.6 million in 2026.
- According to Business Quant data, Revenue over the past three periods registered $243.6 million, $214.3 million, and $202.1 million for Q2 2026, Q1 2026, and Q4 2025 respectively.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Revenue (Qtr) |
|---|---|---|---|---|---|
| 1 | Amgen | 212.54 Bn | 198.55 Bn | 7.24 Bn | 10.05 Bn |
| 2 | Gilead Sciences | 186.84 Bn | 183.58 Bn | 6.22 Bn | 7.80 Bn |
| 3 | Vertex Pharmaceuticals | 129.39 Bn | 121.54 Bn | 2.84 Bn | 3.33 Bn |
| 4 | Regeneron Pharmaceuticals | 82.05 Bn | 74.06 Bn | 3.93 Bn | 4.29 Bn |
| 5 | Moderna | 69.00 Bn | 63.87 Bn | 52.00 Mn | 145.00 Mn |
| 6 | Argenx Se | 61.15 Bn | 55.97 Bn | 1.37 Bn | 1.52 Bn |
| 7 | Alnylam Pharmaceuticals | 32.67 Bn | 29.37 Bn | 992.69 Mn | 1.29 Bn |
| 8 | Biogen | 32.37 Bn | 31.08 Bn | 1.96 Bn | 2.74 Bn |
| 9 | Roivant Sciences | 28.18 Bn | 28.87 Bn | 1.16 Mn | 1.44 Mn |
| 10 | Kiniksa Pharmaceuticals International | 12.19 Bn | 11.66 Bn | 220.03 Mn | 243.60 Mn |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | 243.60 Mn |
| Mar 31, 2026 | 214.27 Mn |
| Dec 31, 2025 | 202.13 Mn |
| Sep 30, 2025 | 180.86 Mn |
| Jun 30, 2025 | 156.80 Mn |
| Mar 31, 2025 | 137.79 Mn |
| Dec 31, 2024 | 122.54 Mn |
| Sep 30, 2024 | 112.21 Mn |
| Jun 30, 2024 | 108.63 Mn |
| Mar 31, 2024 | 79.86 Mn |
| Dec 31, 2023 | 83.40 Mn |
| Sep 30, 2023 | 67.05 Mn |
| Jun 30, 2023 | 71.47 Mn |
| Mar 31, 2023 | 48.35 Mn |
| Dec 31, 2022 | 61.88 Mn |
| Sep 30, 2022 | 99.14 Mn |
| Jun 30, 2022 | 26.97 Mn |
| Mar 31, 2022 | 32.19 Mn |
| Dec 31, 2021 | 18.75 Mn |
| Sep 30, 2021 | 12.10 Mn |
API Access
Kiniksa Pharmaceuticals International Revenue API
Pull this series into your own models, spreadsheets and apps with the Business Quant
Historical Metrics API. The request below matches the chart above — change the
frequency, period or values and it follows. Swap YOUR_API_KEY for your own key.
https://data.businessquant.com/historic?slug=revenue&ticker=KNSA&period=max&api_key=YOUR_API_KEYimport requests
url = "https://data.businessquant.com/historic"
params = {"slug": "revenue", "ticker": "KNSA", "period": "max", "api_key": "YOUR_API_KEY"}
data = requests.get(url, params=params).json()const res = await fetch("https://data.businessquant.com/historic?slug=revenue&ticker=KNSA&period=max&api_key=YOUR_API_KEY");
const data = await res.json();